The exclusive selection of HADLIMA by the US Department of Veterans Affairs to replace HUMIRA on its National Formulary is a significant achievement for Organon. This decision likely indicates a strong confidence in HADLIMA's efficacy and cost-effectiveness for treating autoimmune conditions. As a result, this could lead to increased sales and market penetration for HADLIMA, positively impacting Organon's financial performance and stock price in the short term.